An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT)

Trial Profile

An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Expanded access
  • Acronyms PRECONNECT
  • Sponsors IRIS
  • Most Recent Events

    • 20 Jan 2018 First patient was enrolled in Oct 2016 in this trial. Preliminary safety and efficacy results are anticipated in 2018, as reported in an abstract presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 Baseline characteristics of this trial were presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Results (n=298; As of 7 March 2017) presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top